Eli Lilly Won China's Obesity-Pill Race — and Inherited a 324-Yuan Price Floor

China's drug regulator approved Eli Lilly's orforglipron on November 12, 2026, the first GLP-1 weight-loss pill cleared in the world's second-largest pharmaceutical market. The pill joins a shelf that already holds four weekly injections: Novo Nordisk's Wegovy since late 2024, Eli Lilly's own Mounjaro since January 2025, Innovent Biologics's mazdutide since July 2025 and Pfizer's ecnoglutide since April 2026. Novo Nordisk has had its oral Wegovy application on file since August 27, 2026 with no decision date, so the lead is real for now.

Before a pill was approved, China repriced the injections twice. Nomura estimates cited by Reuters put the negotiated list price for a month of Mounjaro 10mg at 324 yuan, down from 1,758 yuan. Eli Lilly's third-quarter numbers show what that does to the global line: realized prices outside the US fell 29% while US realized prices fell 7%, which the company attributed primarily to Mounjaro's inclusion on China's national reimbursement drug list.

The mechanism is not a discount — it is a single payer with a hard budget, and it moves the line for everyone who wants the volume. Novo Nordisk cut list prices for the top two doses of Wegovy by 48% to 987 yuan and 1,284 yuan a month in some provinces, and Eli Lilly's Mounjaro 10mg was selling for about 445 yuan a month on Meituan, down from 2,180 yuan.

China's GLP-1 market is worth about DKK 6 billion — under a $1 billion equivalent — against more than DKK 20 billion for Europe and Canada, and is expected to reach roughly DKK 20 billion only by 2035. That is the paradox: Beijing is the price-setter for a pool that is still a rounding error, and even the bullish case leaves about 90% of global sales outside China.

The second-order effect is a quality benchmark. Chinese developers have been shipping injections at weight losses the West cannot match — ecnoglutide at -15.4% at week 48, ribupatide at -17.7%, olatorepatide at -18.7% — while their first oral programs land lower, between -9.8% and -12.4%. A Western pill cleared at -11.2% at week 72 turns those oral programs from good enough into behind, at a price the state has already set.

The two Western leaders are answering China in opposite ways. Eli Lilly is building: $3 billion over a decade for Chinese manufacturing, aimed explicitly at oral solid-dose production and supply redundancy for orforglipron, with Beijing-based Pharmaron Beijing named as a local contract development and manufacturing partner. Novo Nordisk is buying: $300 million upfront and up to $2.6 billion for Hengrui's once-weekly oral obesity pill HRS-1596, with rights outside China.

China does not allow prescription-drug advertising to consumers, so the channel is subtler than the market. Eli Lilly ran metro and sleep-clinic messaging, Innovent Biologics used Meituan subway ads and a Suzhou stadium campaign, Pfizer sponsored gym events, and Novo Nordisk staged a health exhibit with state broadcaster CCTV. What matters is the shelf: Lilly led once-weekly GLP-1 sales on Tmall and JD.com in the second quarter, per Jefferies.

The US is running its own net-price experiment on a fixed clock. Novo Nordisk cuts Wegovy to $675 a month from January 1, 2027, with Ozempic down 35%, and Medicare negotiated prices are due to be announced by November 30, 2026 for 2028. Eli Lilly prices Foundayo at $149 a month self-pay in the US, or from $25 with commercial coverage, and has so far held its US list price while its outside-US realized price fell 29%.

The near-term evidence is commercial, not clinical. If Eli Lilly prices Foundayo near the 324-yuan injection floor, the approval defends share; if it prices above it, the pill becomes a brand-building instrument for a market that cannot pay for it. Novo Nordisk's oral Wegovy decision is the cleaner read on whether Lilly's advantage is durable.

The conclusion is deliberately narrow. China did not merely approve a pill; it demonstrated that a state with 1.4 billion people can clear a Western medicine, negotiate its price down by 85% and still attract a crowd of local competitors. For Eli Lilly that is a win on share and a warning on price. For Novo Nordisk it is a lost race and a $2.6 billion ticket to catch up. For everyone else in obesity drugs, Beijing has quietly become the number they will be asked to beat.